No 10Y consistency score yet for revenue — the window needs more comparable quarters.
Valuation vs own 10Y history: P/S N/A · No P/S — trailing revenue unavailable or non-positive.
Annualized revenue (TTM) · by quarter, last 15
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
The latest delayed quote for ArriVent BioPharma, Inc. (AVBP) stock was $28.46 as of Oct 5, 2026, 4:00 PM EDT, up 0.67% from the previous close.
Longer view (total return, dividends reinvested): past 12 months +43.2%
ArriVent BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. The company’s lead development candidate is firmonertinib, a tyrosine kinase inhibitor that is being evaluated in multiple clinical trials across a range of epidermal growth factor receptor mutations (EGFRm) in non-small cell lung cancer (NSCLC), including a Phase 3 clinical trial for treatment of patients with advanced or metastatic EGFRm NSCLC with exon 20 insertion mutations, as well as Phase 1b clinical trials to treat NSCLC patients with activating EGFRm, including P-loop and-alpha-c-helix compressing (PACC) mutations, and classical EGFRm NSCLC patients.
Biotechnology · Newtown Square, PA
Next Earnings Date
Nov 16, 2026
41 days away
EPS Estimate
-1.07
Revenue Est.
$800000.00
Last Quarter Results
EPS
$-1.05
vs Estimate
$-0.98
Revenue
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1AVBP | $1.33B | $28.46 | +0.67% | +43.20% | N/A | N/A | N/A |
| 2DRTS | $1.34B | $14.89 | +0.81% | +243.44% | +8.59% | N/A | vs AVBP |
| 3KARD | $1.36B | $15.24 | +3.04% | N/A | N/A | N/A | vs AVBP |
| 4INBX | $1.39B | $94.56 | -2.51% | +164.01% | +27.64% | N/A | vs AVBP |
| 5KLRA | $1.40B | $10.84 | +4.33% | N/A | N/A | N/A | vs AVBP |
| 6DMRA | $1.24B | $20.22 | -2.08% | +429.27% | -25.05% | N/A | vs AVBP |
forward FY estimate
N/A
$0.00
vs Estimate
$0.00
Consensus Rating
Based on 10 analysts
Average Price Target
$44.70
+57.1% upside
Low
$40.00
Current
$28.46
High
$50.00
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $-1.07 | $-1.05 | $-1.02 | 6 |
| Quarter ending Dec 2026 | $-1.11 | $-1.10 | $-1.09 | 6 |
| Quarter ending Mar 2027 | $-1.00 | $-1.00 | $-1.00 | 2 |
| Quarter ending Jun 2027 | $-1.03 | $-1.03 | $-1.03 | 2 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $-4.31 | $-4.23 | $-4.08 | 7 |
| FY 2027 | $-4.47 | $-3.78 | $-3.31 | 7 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $800000.00 | $800000.00 | $800000.00 | 1 |
| Quarter ending Dec 2026 | $6.05M | $6.05M | $6.05M | 1 |
| Quarter ending Mar 2027 | $6.06M | $6.06M | $6.06M | 1 |
| Quarter ending Jun 2027 | $6.06M | $6.06M | $6.06M | 1 |
Annual
| Period |
|---|
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
| Low |
|---|
| Avg |
|---|
| High |
|---|
| # Analysts |
|---|
| FY 2026 | $27310.00 | $125000.00 | $258159.00 | 7 |
| FY 2027 | $11.08M | $30.28M | $58.18M | 7 |
